SAS Output

26-APR-2018 6:10

MELAN ACCRUAL REPORT - Open and Recently Closed Studies

The REPORT Procedure

Detailed and/or summarized report

Table 1

SWOG/
Support
STUDY R
E
G
O
P
E
N
ARM ACCR.
GOAL
TOTAL
REGS.
REGS.
LAST
12
Month
REGS.
LAST
6
Month
REGS.
LAST
3
Month
REGS.
LAST
30
DAYS
REGS.
LAST
7
DAYS
DATE OF
FIRST
REG.
# of
ACT.
INSTs
# of
CURR
IRBs
SWOG S1320-Adv, BRAF mut, Inter v Contin 1 Y 1 Lead-in Continuous Dosing 280 213 66 37 19 3 1 09/19/2014 230 106
            213 66 37 19 3 1      
 
    2 Y 2 Continuous Dosing 280 86 29 13 5 2 0 09/19/2014    
        3 Intermittent Dosing   84 23 13 6 5 1      
            170 52 26 11 7 1      
 
  S1512-Melan, Adv, Desmoplastic, MK-3475 (pembro) 1 Y 1 MK-3475 (pembrolizumab) 77 7 6 4 2 0 0 02/06/2017 75 39
            7 6 4 2 0 0      
 
  S1616-MELAN, Adv, Ipilimumab Nivolumab 1 Y 1 Ipilimumab 94 2 2 2 1 0 0 10/23/2017   84
        2 Nivolumab + Ipilimumab   6 6 5 2 0 0      
            8 8 7 3 0 0      
 
Yes EA6134-Adv, BRAF mut, D+T/Ipi+Niv vs Ipi+Niv/D+T 1 E Total Registrations   26 11 4 2 1 0 11/03/2015 346 146
            26 11 4 2 1 0      
 
    2 E Total Registrations   7 4 2 2 0 0 11/03/2015    
            7 4 2 2 0 0      
 
  EA6141-Melan, Avd, Nivolumab+Ipi Sargmostim 1 E Total Registrations   36 14 0 0 0 0 03/25/2016 303 120
            36 14 0 0 0 0      
 

26-APR-2018 6:10

MELAN Open Studies with No Registrations

The REPORT Procedure

Detailed and/or summarized report

Table 1

Study Registration/Phase Open Date
S1607 MELAN, Adv, T-VEC, MK-3475 1 Registration 02-Oct-17